KPTI Stock Hub: Karyopharm News, Selinexor and Debt

KPTI stock: dated key data

Accounts and share count: June Form 10-Q; commercial guidance: August results; missed obligation and agreement: September filing; last disclosed forbearance end date (November 1): October 22 extension; Chapter 11 and merger: November 2 release; market reference: Nasdaq. Guidance, historical cash, payment obligations and creditor forbearance measure different things.

KPTI today: regulatory progress does not settle creditor claims

XPOVIO remains a commercial multiple-myeloma product. The myelofibrosis application seeks accelerated approval with a Priority Review request; submission, FDA filing acceptance, review designation and approval are separate decisions. The August announcement expected notice in Q4; as of November 2, the company’s announcements do not report FDA filing acceptance or a review date. Submission disclosure · Current XPOVIO label.

On November 2 the company announced a Restructuring Support Agreement with its existing lenders, noteholders and other key stakeholders. It provides for a merger between Ayrmid Ltd. (parent of Gamida Cell Inc.) and a reorganized Karyopharm, implemented through voluntary Chapter 11 petitions filed in the U.S. Bankruptcy Court for the Southern District of Texas. The company expects to complete the transaction through a Chapter 11 plan, will seek court approval of bidding procedures that allow competing bids, and says it will continue to operate in the ordinary course. It reports commitments for up to $55 million of debtor-in-possession financing from its existing secured lenders which, once approved by the court and together with cash from operations, is expected to support the business during the case. November 2 release.

These steps follow the September forbearance agreement and its extensions, which paused specified remedies without curing the defaults. On common equity, the Form 8-K filed the same day says the Prepackaged Plan provides that holders of the common stock and of the Convertible Preferred Stock will not receive any payment or other distribution on account of those securities, and the company expects its existing equity securities to have no value (Form 8-K); the release lists, among its risk factors, the expected delisting of the common stock from Nasdaq. The June Form 10-Q also raised substantial doubt about going concern. September agreement · October 22 extension.

KPTI stock news: six selected updates

KPTI stock catalysts: dated milestones

• November 2, 2026 · Restructuring Support Agreement and Chapter 11 filingAnnounced · completed

  Voluntary petitions filed in the Southern District of Texas; Ayrmid named lead bidder. The November 1 forbearance deadline is not addressed in the release. November 2 release.

• Date not disclosed · Court approval of bidding procedures and DIP financingPending · company will seek approval

  The release says the company will seek approval of bidding procedures allowing competing proposals; the DIP commitments take effect once approved by the court.

• Q1 2027 · Expected closing of the transactionCompany expectation · subject to the Chapter 11 plan

  Closing is subject to the conditions described in the Chapter 11 plan; the timing is a company expectation.

• Q4 2026 · Myelofibrosis filing acceptance and review designationCompany-expected window · not reported as of November 2

  The August 31 announcement requested Priority Review and awaited FDA filing feedback; the November 2 release does not mention it. Submission disclosure.

• H2 2026 company guidance · SENTRY-2 cohort and EMN29 / XPORT-MM-031Guided windows · no exact day; MM-031 event-driven

  The company guided the 60 mg SENTRY-2 cohort readout and event-driven MM-031 results to H2 before the Chapter 11 filing; the November 2 release gives no update. Registry completion dates are different milestones, and timing can change. August outlook.

Selinexor: the SENTRY endpoint and regulatory distinction

XPORT-EC-042’s missed primary endpoint narrows the development story. Numerical progression-free-survival differences do not establish statistical success. SENTRY results · Proposed regulatory path · Endometrial result · FDA DLBCL labeling action.

KPTI liquidity thresholds, senior claims and dilution

These terms predate the November 2 Chapter 11 filing, whose release does not give the full terms of the Restructuring Support Agreement. September’s agreement includes an early-termination mechanism involving liquidity below $10M, while a separate $25M minimum-liquidity covenant applies after October 10. These thresholds have different functions; neither the October extension nor June cash proves current compliance. Refusal to file or withdrawal of the myelofibrosis application is also a specified potential early-termination event under the agreement.

June principal obligations were approximately $252.6M across term loans and notes, alongside future royalty obligations. The $20M senior preferred fee adds another claim above common equity. The initial $20M preference divided by the $1.62 conversion price implies about 12.35M common shares before later changes, subject to a 4.52M pre-consent issuance cap and a 19.99% holder limit. That is not completed conversion or cash financing. Forbearance terms · Preferred terms · June accounts.

Merlintrader Health Score · KPTI

Editorial assessment dated October 29, 2026: 1×30% + 2×30% + 1×20% + 1×10% + 1×10% = 1.30/5. The scores are from the October 29 assessment, before the November 2 Chapter 11 filing; the pillar texts describe the situation on that date. This measures robustness, not FDA odds, expected recovery, a target price or an investment recommendation.

KPTI red flags

• The company has filed voluntary Chapter 11 petitions; specified payment defaults preceded the filing.
• The Form 8-K filed November 2 says the Prepackaged Plan provides no payment or distribution to holders of common stock and that the company expects existing equity to have no value.
• The release lists the expected Nasdaq delisting of the common stock and effects on common and convertible preferred holders among its risk factors.
• Historical cash does not establish current liquidity or covenant compliance.
• Clinical value does not determine common-equity recovery after senior claims.
• Priority Review was requested; as of November 2 the company has not announced acceptance or a review date.
• SENTRY missed its symptom co-primary endpoint; XPORT-EC-042 missed its primary endpoint.
• Senior preferred conversion and future financing can materially dilute common holders.
• The sale process permits competing bids, and the court must approve bidding procedures and DIP financing.